NOVAREMED
Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019.
“This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.”
Poster Presentation Details:
Presentation Title:
Novaremed is developing NRD.E1, an innovative
therapy for diabetic neuropathic pain - Results from a proof of concept
study
https://www.novaremed.com/wp-content/uploads/2019/05/PS90_Novaremed_NRDE1PoCinDNP_20190503_c.pdf
Presenter:
Sara Mangialaio, MD, PhD, Novaremed
Presentation Date:
May
11, 2019
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel
and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed
is developing NRD.E1, an orally-active small molecule with a
differentiated mechanism of action for the treatment of Diabetic
Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1
showed clinically relevant reduction in patient reported pain. Novaremed
is currently preparing for a global Phase 2b study in DPN, expected to
start in Q4 2019. For more information, visit www.novaremed.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005176/en/
Contact:
Subhasis Roy Chief Operating Officer Tel: +41 79 2075715 Email: subhasis.roy@novaremed.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
Kinaxis to Host Inaugural European User Conference Showcasing Supply Chain Innovators17.9.2025 13:00:00 CEST | Press release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced its inaugural customer conference in Europe. Kinexions EMEA 2025 will be held October 6 – 8 in Amsterdam NL, bringing together global supply chain leaders from ExxonMobil, Bosch, and more. Following the success of Kinexions conferences in North America and Asia, expanding Kinexions into Europe meets the needs of a growing customer community in the region and reflects the growing community of leaders in the region who are driving some of the most innovative and resilient supply chain transformations today. That momentum is reflected in Kinaxis’ 18% year-over-year revenue growth in Europe, underscoring rising demand for AI-driven orchestration on the Kinaxis Maestro® platform. Why It Matters As supply chains face ongoing pressure from the dynamic tariff environment, geopolitical risk, ESG regulation, and many other disruptions, companies are accelerating digital transformation efforts. Kin
Allied Telesis Launches SwitchBlade® x908 Generation 3 to Solve Enterprise and Data Center Scalability Challenges17.9.2025 11:40:00 CEST | Press release
Compact 3U modular chassis delivers capacity-on-demand flexibility and first Allied Telesis 400G support. Enterprises and data centers face mounting challenges in scaling their networks to support AI, video, IoT, and virtualized workloads. Bandwidth demand is rising, yet many organizations are held back by legacy switches, fragmented operations, and the high cost of oversized chassis systems. To address these issues, Allied Telesis today announced the SwitchBlade x908 Generation 3 (SBx908 GEN3), a next-generation modular switch that combines high-density performance, flexible interface modularity, and future-proof scalability in a compact 3U form factor. Customers can expand capacity on demand with a wide range of interface modules, tailoring the platform to their evolving requirements. Why SBx908 GEN3? The SBx908 GEN3 was developed in direct response to customer demand for scalable, space-efficient networking. Its capacity-on-demand model allows customers to start with only the ports
LTIMindtree Partners with Shopify to Launch an AI Commerce Center of Excellence17.9.2025 11:30:00 CEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced a partnership with Shopify, an AI powered commerce platform for enterprises that empowers businesses to launch, manage, and grow their online stores. Leveraging the Shopify platform, LTIMindtree will set up an AI enabled Center of Excellence (CoE) for Digital Commerce that will help global enterprises to transform at the speed of AI and innovate at scale. LTIMindtree Interactive, the AI-led agency unit of LTIMindtree, is driving the next wave of enterprise digital commerce transformation for CMOs across the globe. Shopify, trusted by millions of merchants, provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. Leveraging the Shopify platform, LTIMindtree will power an AI-driven Centre of Excellence to develop a best-in-class CoE that will: Build advanced AI commerce capabilities to help
Alpha’s latest report explores the impact of retail investors on fund finance provision17.9.2025 11:00:00 CEST | Press release
Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends. What does retail investment mean for subscription lines? Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants. While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed. One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom